Antiviral
1 / 1
Failed to load
M&A
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Novo Holdings A/S
PR-M04-22-05Apr 07, 2022
Failed to load
COVID-19 Antiviral
Model Medicines' Oral Anti-COVID-19 Drug Candidate MDL-001 Found to Significantly Reduce Viral Load in Lungs; Accepted into NIH's Antiviral Program for Pandemics (APP)
Model Medicines
PR-M02-22-05Feb 08, 2022
Failed to load
COVID-19 Research
MU Study Identifies Mutations Specific to Omicron Variant
University of Missouri
PR-M01-22-17Jan 25, 2022
Failed to load
Nice Insight Overview
Drug Approval Trends: Significant Acceleration in Recent Years
Nigel Walker
Nice Insight
PAP-Q2-20-NI-001Jul 01, 2020
Failed to load
COVID-19
Q: What is your perspective on how the pharma industry has responded to the COVID-19 pandemic? What lessons have been learned?
Pharma's Almanac
PAP-Q2-20-RT-001Jul 01, 2020
Failed to load
BioMed X Institute Launches Rapid Antiviral Response Platform to Prevent Future Pandemics
BioMed X
PR-M05-20-NI-037May 26, 2020
Failed to load
Licensing
Gilead Licenses Antiviral Candidates from Novartis
Nice Insight
PAO-M08-19-NI-019Aug 15, 2019
Failed to load
Antiviral
Progress on New Antiviral Drugs at Chimerix
Emilie Branch
Pharma's Almanac
PAO-M06-18-NI-019Jun 21, 2018
1 / 1